Abstract
Recently, we have witnessed impressive diagnostic and therapeutic changes for gastrointestinal
cancer patients. New challenges brought by the COVID-19 pandemic have led us to re-evaluate
our work priorities. Thanks to the commendable resilience of both investigators and
patients, however, clinical research never stopped. In addition to conducting cutting-edge
research and serving patients’ needs, as EORTC Gastrointestinal Tract Cancer Group,
we are committed to pursuing educational initiatives beneficial to the entire European
oncology community and beyond. In this regard, we have been providing critical discussions
of new data from major international meetings. In this article, we discuss results
of important selected studies presented at the 2022 ASCO Gastrointestinal Cancer Symposium,
putting them in perspectives and highlighting potential implications for routine practice.
With the number of in-person attendees and practice-changing/informing trials presented,
this meeting represented a milestone in the return to normality as well as in the
fight against cancer.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical Colorectal CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN—a randomized, phase III study.J Clin Oncol. 2014; 32: 2039-2049
- Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study.Lancet Oncol. 2017; 18: 640-653
- HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: implication for further clinical research.Int J Cancer. 2016; 139: 2859-2864
- Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer.N Engl J Med. 2020; 382: 2419-2430
- Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2–positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01).J Clin Oncol. 2022; 40: 242
- Exploratory analysis of the impact of prior immune checkpoint inhibitor (ICI) on trastuzumab deruxtecan (T-DXd; DS-8201) clinical outcomes and biomarkers (BM) in DESTINY-Gastric01 (DG-01), a randomized, phase 2, multicenter, open-label study in patients (pts) with HER2+ advanced gastric or gastroesophageal junction adenocarcinoma.J Clin Oncol. 2020; 38: 322
- Primary analysis of a phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer who progressed on or after a trastuzumab-containing regimen.Ann Oncol. 2021; 32: S1283-S1346
Trastuzumab deruxtecan for subjects with HER2-positive gastric cancer or gastro-esophageal junction adenocarcinoma after progression on or after a trastuzumab-containing regimen (DESTINY-Gastric04). Available at: https://clinicaltrials.gov/ct2/show/NCT04704934?term=destiny+gastric+04&draw=2&rank=1 (Accessed February 20, 2022).
- Dose-escalation and dose-expansion study of trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2+ gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03.J Clin Oncol. 2020; 38: 295
- First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.Lancet. 2021; 398: 27-40
- Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.Lancet. 2021; 398: 759-771
- KEYNOTE-585: phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer.Future Oncol. 2019; 15: 943-952
- Pembrolizumab (pembro) in microsatellite instability-high (MSI-H) advanced gastric/gastroesophageal junction (G/GEJ) cancer by line of therapy.J Clin Oncol. 2020; 38: 430
- Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in patients (pts) with localized microsatellite instability-high (MSI)/mismatch repair deficient (dMMR) oeso-gastric adenocarcinoma (OGA): the GERCOR NEONIPIGA phase II study.J Clin Oncol. 2022; 40: 244
- Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer.N Engl J Med. 2019; 381: 317-327
- Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study.J Clin Oncol. 2020; 38: 1-10
- Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial.Lancet Oncol. 2020; 21: 508-518
- KRYSTAL-1: updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRASG12C mutation.J Clin Oncol. 2022; 40: 519
- Randomized phase III study of sintilimab in combination with modified folfrinox versus folfrinox alone in patients with metastatic and recurrent pancreatic cancer in China: the CISPD3 trial.J Clin Oncol. 2022; 40: 560
- LBA65 The Canadian Cancer Trials Group PA.7 trial: results of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC).Ann Oncol. 2020; 31: S1195
- Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: an open-label, randomized phase IIb trial.Eur J Cancer. 2020; 124: 91-101
- Trybeca-1: a randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with advanced pancreatic adenocarcinoma (NCT03665441).J Clin Oncol. 2022; 40: 518
- Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial.Lancet Oncol. 2015; 16: 839-847
- MAESTRO: a randomized, double-blind phase III study of evofosfamide (Evo) in combination with gemcitabine (Gem) in previously untreated patients (pts) with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC).J Clin Oncol. 2016; 34: 4007
- Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.N Engl J Med. 2020; 382: 1894-1905
- Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.J Clin Oncol. 2022; 40: 379
- Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: randomized expansion of a phase I/II study.J Clin Oncol. 2021; 39: 2991-3001
- Lenvatinib combined with transarterial chemoembolization as first-line treatment of advanced hepatocellular carcinoma: a phase 3, multicenter, randomized controlled trial.J Clin Oncol. 2022; 40: 380
- Adjuvant S-1 versus observation in curatively resected biliary tract cancer: a phase III trial (JCOG1202: ASCOT).J Clin Oncol. 2022; 40: 382
- Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study.Lancet Oncol. 2019; 20: 663-673
- A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1.J Clin Oncol. 2022; 40: 378
- Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.N Engl J Med. 2010; 362: 1273-1281
- Randomized phase III study of etoposide plus cisplatin versus irinotecan plus cisplatin in advanced neuroendocrine carcinoma of the digestive system: a Japan Clinical Oncology Group study (JCOG1213).J Clin Oncol. 2022; 40: 501
- Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.Lancet Oncol. 2017; 18: 1182-1191
- Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer.J Clin Oncol. 2018; 36: 773-779
- First-line nivolumab plus ipilimumab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study.J Clin Oncol. 2022; 40: 161-170
- Pembrolizumab in microsatellite-instability–high advanced colorectal cancer.N Engl J Med. 2020; 383: 2207-2218
- One-year duration of nivolumab plus ipilimumab in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer (mCRC): long-term follow-up of the GERCOR NIPICOL phase II study.J Clin Oncol. 2022; 40: 13
- RECIST and iRECIST criteria for the evaluation of nivolumab + ipilimumab combination in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer (mCRC): results of the GERCOR NIPICOL phase II study.J Immunother Cancer. 2020; 8e001499
- MEK and PD-L1 inhibition in colorectal cancer: a burning blaze turning into a flash in the pan.Lancet Oncol. 2019; 20: 752-753
- Combined treatment with immunotherapy-based strategies for MSS metastatic colorectal cancer.Cancers (Basel). 2021; 13: 6311
- Nivolumab (NIVO) + 5-fluorouracil/leucovorin/oxaliplatin (mFOLFOX6)/bevacizumab (BEV) versus mFOLFOX6/BEV for first-line (1L) treatment of metastatic colorectal cancer (mCRC): phase 2 results from CheckMate 9X8.J Clin Oncol. 2022; 40: 8
- FOLFOXIRI plus bevacizumab (bev) plus atezolizumab (atezo) versus FOLFOXIRI plus bev as first-line treatment of unresectable metastatic colorectal cancer (mCRC) patients: results of the phase II randomized AtezoTRIBE study by GONO.Ann Oncol. 2021; 32: S1294-S1295
- Adaptive mutability of colorectal cancers in response to targeted therapies.Science. 2019; 366: 1473-1480
- Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable, BRAFV600E metastatic colorectal cancer.J Clin Oncol. 2022; 40: 12
- Clinical efficacy of combined BRAF, MEK and PD-1 inhibition in BRAFV600E colorectal cancer patients.Ann Oncol. 2020; 31: S226-S227
- Encorafenib, binimetinib, and cetuximab in BRAF V600E–mutated colorectal cancer.N Engl J Med. 2019; 381: 1632-1643
- Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers.Nat Med. 2020; 26: 566-576
- Neoadjuvant pembrolizumab in localized/locally advanced solid tumors with mismatch repair deficiency.Ann Oncol. 2021; 32: S1211-S1226
- Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study.Lancet. 2018; 391: 2537-2545
- PD-1 blockade alone for mismatch repair deficient (dMMR) locally advanced rectal cancer.J Clin Oncol. 2022; 40: 16
- Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial.Lancet. 2011; 277: 1749-1759
- Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial.Lancet Oncol. 2013; 14: 1077-1085
- First-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS-BRAF wild-type metastatic colorectal cancer elderly patients: The PANDA study.J Clin Oncol. 2020; 38: 4002
- A randomized phase III trial of mFOLFOX7 or CapeOX plus bevacizumab versus 5-FU/l-LV or capecitabine plus bevacizumab as initial therapy in elderly patients with metastatic colorectal cancer: JCOG1018 study (RESPECT).J Clin Oncol. 2022; 40: 10
- Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: individual patient pooled analysis of three cohort studies.Int J Cancer. 2021; 148: 1014-1026
- Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: a prospective cohort study.PLoS Med. 2021; 18e1003620
- Association of circulating tumor DNA dynamics with clinical outcomes in the adjuvant setting for patients with colorectal cancer from an observational GALAXY study in CIRCULATE-Japan.J Clin Oncol. 2022; 40: 9
- FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma.Ann Oncol. 2021; 32: 609-619
A study of zolbetuximab (IMAB362) plus CAPOX compared with placebo plus CAPOX as first-line treatment of subjects with claudin (CLDN) 18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (GLOW). Available at: https://clinicaltrials.gov/ct2/show/NCT03653507 (Accessed February 21, 2022).
A phase 3 efficacy, safety and tolerability study of zolbetuximab (experimental drug) plus mFOLFOX6 chemotherapy compared to placebo plus mFOLFOX6 as treatment for gastric and gastroesophageal junction (GEJ) cancer (Spotlight). Available at: https://clinicaltrials.gov/ct2/show/NCT03504397 (Accessed February 21, 2022).
- A phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of TST001 in patients with locally advanced or metastatic solid tumors.J Clin Oncol. 2022; 40: TPS375
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.Lancet. 2010; 376: 687-697
- Phase 1b/2, open-label, dose-escalation and expansion trial of tucatinib in combination with trastuzumab with and without oxaliplatin-based chemotherapy or pembrolizumab in patients with unresectable or metastatic HER2+ gastrointestinal cancers.J Clin Oncol. 2022; 40: TPS376
- SGNTUC-019: phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations.J Clin Oncol. 2022; 40: TPS3151
- A phase 2, multicenter, open-label study evaluating trastuzumab deruxtecan (T-DXd) for the treatment of select human epidermal growth factor receptor 2 (HER2)-expressing solid tumors (DESTINY-PanTumor02).J Clin Oncol. 2022; 40: TPS623
- A phase 1, first-in-human (FIH) study of adenovirally transduced autologous macrophages engineered to contain an anti-HER2 chimeric antigen receptor (CAR) in subjects with HER2 overexpressing solid tumors.J Clin Oncol. 2022; 40: TPS668
Article Info
Publication History
Published online: April 22, 2022
Accepted:
April 9,
2022
Received:
March 13,
2022
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
